Company intelligence / Profile preview

PaxMedica, Inc.

Tarrytown, New York, United Statespaxmedica.com ↗

Ownership: Public · PXMD
Employees: ~7
Development stage: Phase 2

Overview

Lead candidate PAX-101 (intravenous suramin) is in Phase 3 clinical trials for autism spectrum disorder. The company is developing treatments for disorders with intractable neurologic symptoms.

Therapeutic areas: PsychiatryNeurologyInfectious Diseases
Modalities: Anti-purinergic drug therapies (APT)
Industry: Biotech

Drug pipeline

2 assets

suramin

Phase 2

Indications: Autism Spectrum Disorder

1 more asset in the full pipeline.

Request access →

Partnerships

Research collaboration with PolarMar Health for Phase II clinical trial in autism spectrum disorder for emodin

Financials

Market cap: $63.1K
Total revenue: $0
Enterprise value: $-261.4K

Beyond the preview

Go deeper on PaxMedica, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PaxMedica, Inc..

Explore the full profile